

# ESMO Virtual Advanced Course on Innovation and Emerging Knowledge in Colorectal Cancer

**Programme** 

ESMO VIRTUAL ADVANCED COURSE

11-12 DECEMBER 2020

**Co-Chairs**Julien Taieb, France
Elena Élez, Spain

### ESMO VIRTUAL ADVANCED COURSE PROGRAMME

# INNOVATION AND EMERGING KNOWLEDGE IN COLORECTAL CANCER

11-12 December 2020

**CO-CHAIRS:** Julien Taieb, France **SPEAKERS:** Jean-Baptiste Bachet, France

Elena Élez, Spain Rodrigo Dienstmann, Brazil

Erika Martinelli, Italy

Dominik Modest, Germany Clara Montagut, Spain

Andrea Sartore Bianchi, Italy Jenny Seligmann, United Kingdom

#### **LEARNING OBJECTIVES**

- To learn the biological basis and characterization of Colorectal Cancer (CRC)
- To understand the essentials in the assessment and the value of multidisciplinary management of patients with CRC
- To learn how to integrate and to sequence the available therapies in the management of a patient with advanced CRC integrating molecular and clinical information including direct exposure to real clinical scenarios
- To learn and discuss about future advances in diagnose and treatment of CRC

#### **ACCREDITATION**

The programme of this event has been accredited with **7 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

#### **ACKNOWLEDGEMENTS**

This event is supported by an unrestricted educational grant from



#### ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4 6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org



## Programme timings are to be considered CET (Central European Time)

# Friday, 11 December 2020

15:00-15:10	Welcome and course overview Julien Taieb, FR and Elena Élez, ES
15:10-16:25	Session 1 Biological basis and characterization of CRC
20'	Molecular characterization of CRC and its stroma Andrea Sartore Bianchi, IT
20'	Role of microbiota in CRC Elena Élez, ES
20'	Integrating data in CRC using Artificial Intellingence Rodrigo Dienstmann, BR
15'	Discussion Faculty
16:25-16:40	Break
16:40-18:25	Session 2 Therapeutic approach in the early disease
<b>16:40-18:25</b> 20'	
	Therapeutic approach in the early disease  Optimizing perioperative treatment in rectal cancer
20'	Therapeutic approach in the early disease  Optimizing perioperative treatment in rectal cancer Jean-Baptiste Bachet, FR  Is there a room for neoadjuvant treatment on colon cancer?
20'	Therapeutic approach in the early disease  Optimizing perioperative treatment in rectal cancer Jean-Baptiste Bachet, FR  Is there a room for neoadjuvant treatment on colon cancer? Jenny Seligmann, UK  Potentials of liquid biopsy in the early stage
20' 20' 20'	Therapeutic approach in the early disease  Optimizing perioperative treatment in rectal cancer Jean-Baptiste Bachet, FR  Is there a room for neoadjuvant treatment on colon cancer? Jenny Seligmann, UK  Potentials of liquid biopsy in the early stage Clara Montagut, ES  The Updated Guidelines of Colon Cancer

# Saturday, 12 December 2020

9:00-10:35	Session 3 How to manage specific situations
20'	State-of-the-art treatment of RAS/BRAF native CRC. Must we consider and assess clonal evolution? Erika Martinelli, IT
20'	Right sided and RAS mutant MSS CRC as entities: Prognostic and Therapeutic implications Dominik Modest, DE
20'	Low Prevalence Molecular aberrations in CRC (KRAS G12C, NTRK, BRAF mut, MSI-High, HER2 amplified) Elena Élez, ES
20'	Immunotherapy strategies in CRC Julien Taieb, FR
15'	Discussion Faculty
10:35-10:50	Break
10:35-10:50 10:50-12:50	Workshop sessions 10' Introduction of the topic on real examples presented by speakers 30' Discussion
	Workshop sessions 10' Introduction of the topic on real examples presented by speakers
10:50-12:50 Workshop 1	Workshop sessions 10' Introduction of the topic on real examples presented by speakers 30' Discussion  Management of liver limited disease beyond front line treatment Jean-Baptiste Bachet, FR
10:50-12:50  Workshop 1 40'  Workshop 2	Workshop sessions 10' Introduction of the topic on real examples presented by speakers 30' Discussion  Management of liver limited disease beyond front line treatment Jean-Baptiste Bachet, FR Jenny Seligmann, UK  Identifying advanced CRC patients for comprehensive molecular profiling: Who and When Clara Montagut, ES